All In MedTech

Device Trial Radar · NCT07875270

Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test

Usability and Clinical Validation of the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Oct 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
CorDx, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 15, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a prospective study for the clinical validation of the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test for the qualitative detection and differentiation of SARS-CoV-2, Influenza A, Influenza B and RSV in AN samples. Results from the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test will be compared to results from a 510(k) cleared highly sensitive, multi-analyte reverse transcriptase polymerase chain reaction (RT-PCR) test for SARS-CoV-2, Influenza A, Influenza B and RSV, such as the 510(k) cleared Cepheid Xpert Xpress CoV-2/Flu/RSV plus (K250995).

Conditions

  • SARS-CoV-2 Infection
  • Influenza A
  • Influenza B
  • RSV

Interventions

  • Flu A/B/COVID-19 + RSV Multiplex Rapid TestDevice

    The Flu A/B/COVID-19 + RSV Multiplex Rapid Test is an investigational lateral flow immunoassay intended for the qualitative detection and differentiation of Influenza A, Influenza B, SARS-CoV-2, and respiratory syncytial virus (RSV) antigens. Participants will perform the investigational test according to the provided instructions. Test results will be evaluated for diagnostic performance against a reference molecular assay, and usability assessments will be conducted according to the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Performance of CorDx Tyfast Flu A/B & COVID-19 + RSV Multiplex Rapid Test measured by agreement with RT-PCRTime frame: The estimated length of the sample collection and testing phase is expected to be 6~35 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CorDx

    Alpharetta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.